carbon tetrachloride*hydrogen chloride | 160208-69-5

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代烷
• 英文名称: carbon tetrachloride*hydrogen chloride
• 英文别名: Hydron;tetrachloromethane;chloride
• CAS: 160208-69-5
• 化学式: CCl₄*ClH
• 分子量: 190.284
• InChiKey: WUDCWOBPQISYIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.97
• 重原子数：
  6
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  1
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  四氯化碳 在 HCl 作用下， 以 四氯化碳 为溶剂， 生成 carbon tetrachloride*hydrogen chloride
  参考文献：
  名称：

  Iohanson, A. V.; Broun, E. B., Optika i Spektroskopiya, 1966, vol. 20, p. 21 - 23

  摘要：

  DOI：

文献信息

• [EN] A NEW PROCESS<br/>[FR] NOUVEAU PROCEDE
  申请人：ASTRA AKTIEBOLAG

  公开号：WO1998046586A1

  公开（公告）日：1998-10-22

  (EN) A process for the manufacture of the racemic compound of formula (I), its $i(R)-enantiomer (formula $i(R)-(I)) and its $i(S)-enantiomer (formula $i(S)-(I)), and pharmaceutically acceptable salts and/or solvates thereof, as well as new intermediates obtained and used in the process.(FR) L'invention concerne un procédé permettant de préparer le composé racémique de formule (I), son énantiomère $i(R) (formule $i(R)-(I)) et son énantiomère $i(S) (formule $i(S)-(I)) et leurs sels et/ou solvats pharmaceutiquement tolérables, ainsi que de nouveaux produits intermédiaire obtenus et utilisés dans ce procédé.

  一种制备式(I)的外消旋化合物及其$i(R)-对映体(式$i(R)-(I))和$i(S)-对映体(式$i(S)-(I))，以及其药学上可接受的盐和/或溶剂化物的方法，以及在该过程中获得和使用的新中间体。
• Methods For Purifying Trans-(-) Delta9-Tetrahydrocannabinol And Trans-(+)-Delta9-Tetrahydrocannabinol
  申请人：Gutman Arie L.

  公开号：US20090298930A1

  公开（公告）日：2009-12-03

  Methods for making trans-(−)-Δ 9 -tetrahydrocannabinol and trans-(+)-Δ 9 -tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ 9 -tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-Δ 9 -tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ 9 -tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of trans-(−)-Δ 9 -tetrahydrocannabinol and trans-(+)-Δ 9 -tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(−)-Δ 9 -tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.

  本文披露了制备反式-(−)-Δ9-四氢大麻酚和反式-(+)-Δ9-四氢大麻酚的方法。在一种实施方式中，通过让包含(±)-Δ9-四氢大麻酚的组合物在手性固定相上分离，制备了一种反式-(−)-Δ9-四氢大麻酚组合物，其中反式-(−)-Δ9-四氢大麻酚的重量占反式-(−)-Δ9-四氢大麻酚和反式-(+)-Δ9-四氢大麻酚总量的至少约99%。本发明还涉及治疗或预防疼痛等病症的方法，包括向需要的患者施用至少98%纯度的反式-(−)-Δ9-四氢大麻酚的有效剂量，基于大麻素的总重量。
• METHODS FOR PURIFYING TRANS-(-)-DELTA9-TETRAHYDROCANNABINOL AND TRANS-(+)-DELTA9-TETRAHYDROCANNABINOL
  申请人：Purdue Pharma L.P.

  公开号：US20130171259A1

  公开（公告）日：2013-07-04

  Methods for making trans-(−)-Δ 9 -tetrahydrocannabinol and trans-(+)-Δ 9 -tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ 9 -tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-Δ 9 )-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ 9 -tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of trans-(−)-Δ 9 -tetrahydrocannabinol and trans-(+)-Δ 9 -tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(−)-Δ 9 -tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.

  本文公开了制备反式-(−)-Δ9-四氢大麻酚和反式-(+)-Δ9-四氢大麻酚的方法。在一种实施例中，通过让包含(±)-Δ9-四氢大麻酚的组成物在手性固定相上分离，制备出反式-(−)-Δ9-四氢大麻酚组成物，其中反式-(−)-Δ9-四氢大麻酚的重量占反式-(−)-Δ9-四氢大麻酚和反式-(+)-Δ9-四氢大麻酚总量的至少约99%。本发明还涉及治疗或预防疼痛等疾病的方法，包括向需要治疗的患者投与至少约98%纯度的反式-(−)-Δ9-四氢大麻酚，其基于大麻素总重量计算。
• METHODS FOR PURIFYING TRANS-(-)-Delta9-TETRAHYDROCANNABINOL AND TRANS-(+)-Delta9-TETRAHYDROCANNABINOL
  申请人：SVC Pharma LP

  公开号：US20150126596A1

  公开（公告）日：2015-05-07

  Methods for making trans-(−)-Δ 9 -tetrahydrocannabinoI and trans-(+)-Δ 9 -tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ 9 -tetrahydrocannabinoI composition is prepared by allowing a composition comprising (±)-Δ 9 -tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ 9 -tetrahydrocannabinoI composition comprising at least about 99% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of trans-(−)-Δ 9 -tetrahydrocannabinol and trans-(+)-Δ 9 -tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(−)-Δ 9 -tetrahydrocannabinoI having a purity of at least about 98% based on the total weight of cannabinoids.

  本文披露了制备反式-(−)-Δ9-四氢大麻酚和反式-(+)-Δ9-四氢大麻酚的方法。在一种实施例中，通过让包含(±)-Δ9-四氢大麻酚的组合物在手性固定相上分离，制备出含有至少约99%按重量计的反式-(−)-Δ9-四氢大麻酚的组合物，基于反式-(−)-Δ9-四氢大麻酚和反式-(+)-Δ9-四氢大麻酚的总量。本发明还涉及用含有至少约98%按重量计的大麻素总量的反式-(−)-Δ9-四氢大麻酚的有效量，治疗或预防疼痛等病症的方法。
• METHODS FOR PURIFYING TRANS-(-)-Δ9-TETRAHYDROCANNABINOL AND TRANS-(+)-Δ9 TETRAHYDROCANNABINOL
  申请人：SVC Pharma LP

  公开号：US20160199344A1

  公开（公告）日：2016-07-14

  Methods for making trans-(−)-Δ 9 -tetrahydrocannabinol and trans-(+)-Δ 9 -tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ 9 -tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-Δ 9 -tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ 9 -tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of trans-(−)-Δ 9 -tetrahydrocannabinol and trans-(+)-Δ 9 -tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(−)-Δ 9 -tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.

  本文披露了制备反式（-）- Δ9-四氢大麻酚和反式（+）- Δ9-四氢大麻酚的方法。在一种实施例中，通过让包含（±）- Δ9-四氢大麻酚的组合物在手性固定相上分离，制备了反式（-）- Δ9-四氢大麻酚组合物，其中反式（-）- Δ9-四氢大麻酚的重量占反式（-）- Δ9-四氢大麻酚和反式（+）- Δ9-四氢大麻酚总量的至少约99％。本发明还涉及治疗或预防疼痛等症状的方法，包括向需要治疗的患者施用至少约98％的纯度的反式（-）- Δ9-四氢大麻酚的有效量，基于大麻素的总重量。